NASDAQ:PRTA - Prothena Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$14.94 +0.04 (+0.27 %)
(As of 07/16/2018 06:00 AM ET)
Previous Close$14.94
Today's Range$14.62 - $15.00
52-Week Range$10.43 - $70.00
Volume342,156 shs
Average Volume731,713 shs
Market Capitalization$594.94 million
P/E Ratio-3.67
Dividend YieldN/A
Prothena logoProthena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases in the neuroscience and orphan categories. The company is developing antibody-based product candidates that include NEOD001, a monoclonal antibody that is in Phase III and Phase IIb clinical trials for the treatment of AL amyloidosis; PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, a monoclonal antibody that is under preclinical development for the treatment of ATTR Amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, progressive supranuclear palsy, frontotemporal dementia, chronic traumatic encephalopathy, and other tauopathies; Aß, or Amyloid Beta for the treatment of Alzheimer's disease; ALECT2 for ALECT2 amyloidosis; TDP-43 for amyotrophic lateral sclerosis and frontotemporal dementia; and Sortilin for frontotemporal dementia and neuro inflammation. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Celgene Corporation to develop new therapies for a range of neurodegenerative diseases. Prothena Corporation plc was incorporated in 2012 and is headquartered in Dún Laoghaire, Ireland.

Receive PRTA News and Ratings via Email

Sign-up to receive the latest news and ratings for PRTA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations


Debt-to-Equity RatioN/A
Current Ratio15.11
Quick Ratio15.11


Trailing P/E Ratio-3.67
Forward P/E Ratio-4.06
P/E GrowthN/A

Sales & Book Value

Annual Sales$27.52 million
Price / Sales21.62
Cash FlowN/A
Price / CashN/A
Book Value$10.59 per share
Price / Book1.41


EPS (Most Recent Fiscal Year)($4.07)
Net Income$-153,230,000.00
Net Margins-606.09%
Return on Equity-38.08%
Return on Assets-30.02%


Outstanding Shares39,820,000
Market Cap$594.94

The Truth About Cryptocurrencies

Prothena (NASDAQ:PRTA) Frequently Asked Questions

What is Prothena's stock symbol?

Prothena trades on the NASDAQ under the ticker symbol "PRTA."

How were Prothena's earnings last quarter?

Prothena Co. PLC (NASDAQ:PRTA) issued its earnings results on Tuesday, May, 8th. The biotechnology company reported ($1.26) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($1.23) by $0.03. The biotechnology company earned $0.23 million during the quarter, compared to the consensus estimate of $31.45 million. Prothena had a negative return on equity of 38.08% and a negative net margin of 606.09%. View Prothena's Earnings History.

When is Prothena's next earnings date?

Prothena is scheduled to release their next quarterly earnings announcement on Tuesday, August, 14th 2018. View Earnings Estimates for Prothena.

What price target have analysts set for PRTA?

11 Wall Street analysts have issued twelve-month target prices for Prothena's shares. Their forecasts range from $12.00 to $100.00. On average, they anticipate Prothena's stock price to reach $51.8182 in the next year. This suggests a possible upside of 246.8% from the stock's current price. View Analyst Ratings for Prothena.

What is the consensus analysts' recommendation for Prothena?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prothena in the last year. There are currently 1 sell rating, 5 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold."

What are Wall Street analysts saying about Prothena stock?

Here are some recent quotes from research analysts about Prothena stock:
  • 1. Cantor Fitzgerald analysts commented, "We are reiterating our Overweight rating for PRTA stock and we are raising our PT to $18 from $14 based on our analysis of the potential value of PRTA’s drug discovery platform and management’s recently announced restructuring plan." (6/15/2018)
  • 2. According to Zacks Investment Research, "The wider-than-expected loss in the first quarter was disappointing. The discontinuation of development of NEOD001 is a big setback for the company as it was the lead candidate. Nevertheless, Prothena’s license agreement with Roche for the development and commercialization of selected antibodies targeting alpha-synuclein is a big positive as it not only boosts pipeline development but also provides it with funds in the form of research reimbursement and milestone payments. The company recently entered into an agreement with Celgene as well.  However,  Prothena is highly dependent on its collaboration partners for the development of its candidates. The company itself does not have enough resources to independently conduct studies on its candidates. Moreover, due to disappointing data from a phase Ib study, the company will not advance PRX003 into mid-stage development. Shares have performed worse than the industry in the last six months." (5/22/2018)

Who are some of Prothena's key competitors?

Who are Prothena's key executives?

Prothena's management team includes the folowing people:
  • Mr. Gene G. Kinney, Pres, CEO & Director (Age 49)
  • Mr. Tran B. Nguyen, Chief Financial Officer (Age 44)
  • Mr. Arthur W. Homan, Chief Legal Officer (Age 59)
  • Ms. Carol D. Karp, Chief Regulatory Officer (Age 65)
  • Dr. Martin Koller, Consultant (Age 67)

Has Prothena been receiving favorable news coverage?

News coverage about PRTA stock has trended positive on Monday, Accern Sentiment reports. The research firm ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Prothena earned a daily sentiment score of 0.43 on Accern's scale. They also gave news coverage about the biotechnology company an impact score of 45.66 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

How do I buy shares of Prothena?

Shares of PRTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Prothena's stock price today?

One share of PRTA stock can currently be purchased for approximately $14.94.

How big of a company is Prothena?

Prothena has a market capitalization of $594.94 million and generates $27.52 million in revenue each year. The biotechnology company earns $-153,230,000.00 in net income (profit) each year or ($4.07) on an earnings per share basis. Prothena employs 125 workers across the globe.

How can I contact Prothena?

Prothena's mailing address is ADELPHI PLAZA UPPER GEORGE`S STREET, DUN LAOGHAIRE L2, A96 T927. The biotechnology company can be reached via phone at 353-1236-2500 or via email at [email protected]

MarketBeat Community Rating for Prothena (NASDAQ PRTA)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  362 (Vote Outperform)
Underperform Votes:  212 (Vote Underperform)
Total Votes:  574
MarketBeat's community ratings are surveys of what our community members think about Prothena and other stocks. Vote "Outperform" if you believe PRTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRTA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/16/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.